Analysis of antigen-specific T-cell responses with synthetic peptides—what kind of peptide for which purpose?

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1+ leukemias

“…In certain cases, responses to a specific nonamer sequence within a 15-mer might be altered by differences in the susceptibility of amino acid sequences flanking the nonamer to editing by exoproteases. 48 However, in direct comparisons, the For personal use only. on May 11, 2018.…”

“…In this case, peptide 41 was found to elicit both CD4 ϩ and CD8 ϩ IFN␥ ϩ T-cell responses ( Figure 3A). Fine mapping of the 11-mers within peptide 41 eliciting the CD4 ϩ IFN␥ ϩ T-cell response ( Figure 3A) suggested the [38][39][40][41][42][43][44][45][46][47][48] LDFAPPGASAY peptide as the most immunogenic sequence inducing both CD4 ϩ and CD8 ϩ IFN␥ ϩ T-cell responses. Strikingly, peptide 41-sensitized T cells lysed PHA blasts sensitized with either the 9-amino acid sequence ( 38-46 LDFAPPGAS) or the 11-amino acid sequence ( 38-48 LDFAPPGASAY), but did not lyse PHA blasts loaded with the 36-46 PVLDFAPPGAS or 37-47 VLDFAPPGASA 11-mers.…”

Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy

“…28 It is possible that pentadecapeptides containing these potentially immunogenic HLA-A*0201-binding sequences cannot be adequately or appropriately digested by the ectopeptidases in the cell cultures, which have been shown to trim off amino acid sequences from the pentadecapeptides not fitting in the groove of the presenting HLA allele. 31,32 Experiments to address this possibility are in progress. However, it also is possible that these other sequences of CMVpp65 are not efficiently processed and presented by CMV-infected cells and therefore do not elicit a major cytotoxic T-cell response.…”

Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer

“…TAL lines were tested by IFN-g ELISPOT for recognition of (a) predicted minimal peptides (Supplementary Tables S1-S3) and (b) overlapping 15-mer peptides corresponding to all of the mutations found in the respective patient's tumor samples. This dual strategy captured the benefits of epitope prediction while additionally providing unbiased coverage of all possible MHC class I epitopes and many class II epitopes (39). We tested all identified nonsynonymous mutations except those that were present in germline (e.g., BRCA1), or resulted in nontranslated genes (e.g., SPATS2…”